Esperion Therapeutis.Inc. buy Quitte
Start price
20.01.16
/
50%
€14.56
Target price
21.07.16
€17.50
Performance (%)
-32.35%
End price
21.07.16
€9.85
Summary
This prediction ended on 21.07.16 with a price of €9.85. Massive losses of -32.35% were the result for the BUY prediction by Quitte. Quitte has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Esperion Therapeutis.Inc. | - | - | - | - |
| iShares Core DAX® | 0,85 % | 1,37 % | 2,61 % | 52,29 % |
| iShares Nasdaq 100 | -0,99 % | -3,84 % | 25,55 % | 78,88 % |
| iShares Nikkei 225® | -1,78 % | -8,53 % | 42,81 % | 65,51 % |
| iShares S&P 500 | 0,06 % | 0,61 % | 21,57 % | 63,55 % |
Comments by Quitte for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
Jammertal ade
irgendwann muss das was werden
(Laufzeit überschritten)